Skip to main content

Zevra Therapeutics, Inc.

corporate_fare Company Profile

Zevra Therapeutics, Inc.

ZVRA·NASDAQ·Life Sciences·CIK 0001434647

Zevra Therapeutics, Inc. is a commercial-stage company focused on developing and delivering therapies for people with rare diseases. The company's lead product, MIPLYFFA, is marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease. MIPLYFFA was approved by the U.S. Food and Drug Administration (FDA) on September 20, 2024, for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older, and became commercially available in the United States in November 2024. The company also has another product, OLPRUVA, which remains commercially available. Zevra Therapeutics is advancing the development of its clinical stage asset, celiprolol, and plans to expand its pipeline through inorganic growth. In May 2022, the company purchased all assets and operations of Orphazyme A/S related to arimoclomol. The name Zevra, derived from the Greek word for zebra, reflects the company's focus on rare diseases.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for ZVRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ZVRA spans 10-Q, 8-K, DEF 14A, PRE 14A.

Recent high-impact activity:

  • CHMP Rejects EU Marketing Application for Arimoclomol, EC Decision Due Within 67 Days
  • Zevra 10-Q: Q3 Net Income $19.2M, Nine-Month Net Income $65.9M, $270.9M Cash
  • Zevra Q3 Revenue Jumps 45% to $37.8M as MIPLYFFA Hits $34M; Swings to $19.2M Profit
  • Zevra Q2 Revenue Surges 53% to $39.7M, Beats Consensus; Cash Pile Grows to $260M After Debt Payoff
  • Zevra Q2 Revenue Jumps 53% to $39.7M, Crushing Estimates on MIPLYFFA Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$106.47M
Net Income
$83.23M
Diluted EPS
$1.35
Op. Cash Flow
-$1.6M
Free Cash Flow
-$2.43M
Operating Income
-$62.94M
Cash & Equivalents
$62.41M
Total Debt
$61.93M
Debt / Equity
0.40×
Net Margin
78.2%
Shares Outstanding
56.85M sh
Source: 10-K · filed 2026-03-09 · accession 0001434647-26-000011

Short Interest & Short Volume

9.50 days to cover

FINRA reported short interest of 6,556,877 shares in ZVRA as of the October 30, 2026 settlement, a 5.3% increase from the prior period — about 9.5 days to cover at its recent average daily volume. On November 20, 2026, 45.7% of ZVRA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,556,877 shares as of October 30, 2026
Change vs prior period▲ 5.3%
Days to cover9.50 at avg daily volume of 690,195
Daily short volume (FINRA facilities)45.7% of 417,672 shares on November 20, 2026
5-day average short volume44.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with Z →
$8.68 -0.87% today
52-week range · as of 2026-11-03 $8.01 – $15.04
Market cap
$521.26M
Volume
1.2M (1.2× avg)
3-mo avg 987.7K
Live data · 2026-11-21 19:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZVRA - Latest Insights

ZVRA
Nov 13, 2026, 6:26 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.10
Real-time Price: $8.68 info
Change: -$1.42 (-14%) info
Market Cap: $521.26M info
ZVRA
Nov 03, 2026, 5:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.50
Real-time Price: $8.68 info
Change: -$1.82 (-17%) info
Market Cap: $521.26M info
ZVRA
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.26
Real-time Price: $8.68 info
Change: -$1.58 (-15%) info
Market Cap: $521.26M info
ZVRA
Aug 05, 2026, 5:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.50
Real-time Price: $8.68 info
Change: -$1.82 (-17%) info
Market Cap: $521.26M info
ZVRA
Aug 05, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.60
Real-time Price: $8.68 info
Change: -$1.92 (-18%) info
Market Cap: $521.26M info
ZVRA
Jun 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.42
Real-time Price: $8.68 info
Change: -$3.74 (-30%) info
Market Cap: $521.26M info
ZVRA
Jun 11, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.50
Real-time Price: $8.68 info
Change: -$4.82 (-36%) info
Market Cap: $521.26M info
ZVRA
May 06, 2026, 5:14 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $11.22
Real-time Price: $8.68 info
Change: -$2.54 (-23%) info
Market Cap: $521.26M info
ZVRA
May 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.39
Real-time Price: $8.68 info
Change: -$2.71 (-24%) info
Market Cap: $521.26M info
ZVRA
Apr 20, 2026, 9:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.60
Real-time Price: $8.68 info
Change: -$1.92 (-18%) info
Market Cap: $521.26M info
ZVRA
Apr 06, 2026, 9:01 AM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $9.47
Real-time Price: $8.68 info
Change: -$0.786 (-8%) info
Market Cap: $521.26M info
ZVRA
Mar 16, 2026, 4:45 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $9.89
Real-time Price: $8.68 info
Change: -$1.21 (-12%) info
Market Cap: $521.26M info
ZVRA
Mar 16, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.15
Real-time Price: $8.68 info
Change: -$1.47 (-14%) info
Market Cap: $521.26M info
ZVRA
Mar 09, 2026, 4:23 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $11.01
Real-time Price: $8.68 info
Change: -$2.33 (-21%) info
Market Cap: $521.26M info
ZVRA
Mar 09, 2026, 4:20 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.60
Real-time Price: $8.68 info
Change: -$1.92 (-18%) info
Market Cap: $521.26M info
ZVRA
Mar 09, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $11.03
Real-time Price: $8.68 info
Change: -$2.35 (-21%) info
Market Cap: $521.26M info
ZVRA
Feb 02, 2026, 5:18 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $9.36
Real-time Price: $8.68 info
Change: -$0.676 (-7%) info
Market Cap: $521.26M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets